Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

NCT02575300 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Carcinoid Tumors
Pancreatic NET

Interventions

DRUG: Ibrutinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]